drugset / Trial / NCT06584071
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study to evaluate the preliminary efficacy, safety and pharmacokinetics of PM8002 combined with PM1009 in Patients with first-line Hepatocellular Carcinoma.
Timeline
- Start
- 2024-12
- Primary completion
- 2026-10
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Comparator | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | PM1009 | Unknown | — | — |
| Subject | Pumitamig | Protein / enzyme biologic | — | Intravenous |